[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640310":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":11,"centralContacts":25,"locations":31,"responsibleParty":95,"collaborators":11,"id":97,"slug":98,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":99,"sex":105,"minAge":106,"maxAge":11,"enrollmentInfo":107,"targetDuration":11,"studyType":110,"phases":111,"briefSummary":113,"conditions":114,"keywords":120,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},{"fullName":5,"class":6},"Aktis Oncology, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"[225Ac]Ac-AKY-2519","EXPERIMENTAL",null,[13,14],"Drug: [225Ac]Ac-AKY-2519 (therapeutic)","Drug: [64Cu]Cu-AKY-2519 (imaging)",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":11},"DRUG","[225Ac]Ac-AKY-2519 (therapeutic)","\\[225Ac\\]Ac-AKY-2519 Injection",[9],{"type":17,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"[64Cu]Cu-AKY-2519 (imaging)","\\[64Cu\\]Cu-AKY-2519 Injection",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":11,"email":30},"Tiffany Wang, MD","CONTACT","+1-857-216-8482","AKY-2519-01inquiries@aktisoncology.com",[32,51,66,80],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Hoag Memorial Hospital Presbyterian","RECRUITING","Irvine","California","92618","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-117.82311,33.66946,{"lat":44,"lon":43},[47],{"name":48,"role":28,"phone":49,"phoneExt":11,"email":50},"Gary Ulaner","949-557-0285","gary.ulaner@hoag.org",{"facility":52,"status":34,"city":53,"state":54,"zip":55,"country":38,"countryCode":39,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Biogenix Molecular, LLC","Miami","Florida","33165",{"type":41,"coordinates":57},[58,59],-80.19366,25.77427,{"lat":59,"lon":58},[62],{"name":63,"role":28,"phone":64,"phoneExt":11,"email":65},"Study Coordinator","786-791-1799","jjoseph@cira-health.com",{"facility":67,"status":34,"city":68,"state":69,"zip":70,"country":38,"countryCode":39,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"BAMF Health","Grand Rapids","Michigan","49503",{"type":41,"coordinates":72},[73,74],-85.66809,42.96336,{"lat":74,"lon":73},[77],{"name":63,"role":28,"phone":78,"phoneExt":11,"email":79},"616-330-2735","ResearchClinicalTeam@bamfhealth.com",{"facility":81,"status":34,"city":82,"state":83,"zip":84,"country":38,"countryCode":39,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"XCancer","Omaha","Nebraska","68130",{"type":41,"coordinates":86},[87,88],-95.94043,41.25626,{"lat":88,"lon":87},[91],{"name":92,"role":28,"phone":93,"phoneExt":11,"email":94},"Tony Romero","402-697-2229","tony@xcancer.com",{"type":96,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100640310","phase-1-a-study-of-225acac-aky-2519-in-patients-with-metastatic-castration-resistant-prostate-cancer-100640310",false,"NCT07581184","A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer","BActinium-1: A Phase 1b, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Intravenous Administration of B7-H3 Radiopharmaceutical ([225Ac]Ac-AKY-2519) in Metastatic Castration-Resistant Prostate Cancer","BActinium-1","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histologic or cytologic confirmation of prostatic adenocarcinoma\n* ECOG Performance Status of 0 or 1\n* Adequate end-organ function\n* Ability to give informed consent and comply with study requirements\n* Patients with CNS metastases are eligible if they have received therapy and are neurologically stable, asymptomatic and not receiving corticosteroids\n* Castrate levels of serum testosterone (\\\u003C 50 ng\u002FdL)\n* Documented disease progression on most recent prior line of therapy, either by PSA or imaging-based progression\n* Cohort B: Received 2 or more prior doses of 177Lu-PSMA-617 (PLUVICTO)\n\nExclusion Criteria:\n\n* Prior treatment with more than 2 Androgen receptor pathway inhibitors (ARPIs) and\u002For more than 1 taxane-based therapy in the mCRPC setting\n* Prior treatment with a targeted radiotherapy\n\n  o Exception: Cohort B is required to have had at least 2 prior doses of 177Lu-PSMA-617 (PLUVICTO)\n* Prior treatment with a B7-H3 targeted therapy\n* Received an investigational agent within the previous 28 days\n* Impaired cardiac function or clinically significant cardiac disease\n* Concurrent serious medical condition that would impair study participation or impact the assessment of treatment related toxicity","MALE","18 Years",{"count":108,"type":109},138,"ESTIMATED","INTERVENTIONAL",[112],"PHASE1","This is a Phase 1b, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of \\[64Cu\\]Cu-AKY-2519 and\u002For \\[225Ac\\]Ac-AKY-2519, as well as the preliminary anti-tumor activity of \\[225Ac\\]Ac-AKY-2519 in participants with metastatic castration-resistant prostate cancer (mCRPC) with and without prior exposure to 177Lu-PSMA-617 (PLUVICTO™).",[115,116,117,118,119],"Castration Resistant Metastatic Prostate Cancer","Prostate Cancer","mCRPC (Metastatic Castration-resistant Prostate Cancer)","mCRPC","B7H3",[121,103,122,123],"AKY-2519","AKY-2519-01","B7-H3","2026-07-13",{"date":126,"type":127},"2026-07-14","ACTUAL",{"date":129,"type":109},"2026-07",{"date":131,"type":109},"2032-06",{"name":5,"class":6},4]